For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.
2000 Galloping Hill Rd
Kenilworth, New Jersey 07033-1310
Phone: 19087404000
www.merck.com
US pharma giant Merck & Co is to buy CN201, an investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from privately-held Chinese biotech Curon Biopharmaceutical.
Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
On CNBC''s “Mad Money Lightning Round,” Jim Cramer recommended buying Merck & Co., Inc . (NYSE: MRK ). “I have tremendous, tremendous faith in what Robert Davis [CEO of Merck] is doing,” he added. When asked about Teladoc Health, Inc (NYSE: TDOC ), he said, “What''s going on there, right now we''ve got this Cathie Wood , she sells the stock almost every day. She bought it much higher, it''s really painful to watch.” Fortinet, Inc . (NASDAQ: FTNT ) reported a “very good” quarter, he said. “I remain committed to Nikesh Arora [CEO of Palo Alto … Full story available on Benzinga.com
Abnormal B cells can cause a range of diseases, from autoimmune diseases to cancers.
No summary available.
KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Friday said it has agreed to acquire CN201, an investigational bispecific antibody for the treatment of B-cell associated diseases from Curon B…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases. Jetzt den vollständigen Artikel lesen
Merck to acquire novel bispecific antibody CN201 for $700M upfront, expanding its oncology pipeline. Deal includes $600M in potential milestones. Learn about the promising treatment for lymphoma and leukemia.
On Thursday, Merck & Co Inc (NYSE: MRK ) announced discontinuing the Phase 3 KeyVibe-008 trial based on an independent Data Monitoring Committee (DMC) recommendation . The trial is evaluating the investigational fixed-dose combination (coformulation) of vibostolimab and Keytruda (pembrolizumab), in combination with chemotherapy, compared to Roche Holdings AG’s (OTC: RHHBY ) Tecentriq (atezolizumab) in combination with chemotherapy, for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Also Read: FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug . At a pre-planned analysis, data showed that the primary endpoint of overall … Full story available on Benzinga.com
Merck is winding down a late-stage test of its anti-TIGIT candidate vibostolimab in small-cell lung cancer after it showed early signs of poor efficacy, in another blow to the TIGIT space. The Phase 3 KeyVibe-008 trial was investigating a fixed-dose combination of vibostolimab with Keytruda plus standard-of-care chemotherapy. These therapies